Adherence to treatment in Parkinson's disease: A multicenter exploratory study with patients from six Latin American countries

Gonzalo Sebastián Castro, Carol Miroslava Aguilar-Alvarado, Carlos Zúñiga-Ramírez, Michel Sáenz-Farret, Elisa Otero-Cerdeira, Marcos Serrano-Dueñas, Héctor Alberto González-Usigli, Oscar Bernal, Roberto Leal-Ortega, Ingrid Estrada-Bellmann, Jesús D. Meléndez-Flores, Marcelo Miranda-Cabezas, Héctor Rubén Martínez-Hernández, Juan Carlos Giugni, Koni Katerin Mejía-Rojas, Nicanor Mori, Gabriela Beatriz Raina, Cynthia Lorena García Fernández, Cristina Pecci, Neri Alejandro Álvarez-VillalobosFederico Micheli

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

4 Citas (Scopus)


Background: Adherence to treatment in Parkinson's disease (PD) is compromised due to the need for multiple therapies, comorbidities related to aging, and the complexity of therapeutic schemes. In the present study, we aimed to explore adherence to treatment in groups of PD patients from six Latin-American (LA) countries and identify its associated demographic and clinical parameters. Methods: A multicenter, cross-sectional, exploratory study was conducted from September 2016 to March 2017. Treatment adherence was assessed using the simplified medication adherence questionnaire (SMAQ), applied to patients and caregivers. Sociodemographic and clinical variables (MDS-UPDRS Part III-IV, MMSE, Beck Depression Inventory-II (BDI-II)) were recorded. Results: Eight hundred patients from six LA countries were evaluated. Nonadherence was reported in 58.25% of the population, according to patients. The most frequent issues were forgetfulness and correct timing of doses. A high level of agreement in adherence prevalence and most SMAQ items were observed between patients and their caregivers. The nonadherent population had a significantly higher proportion of unemployment, free access to medication, troublesome dyskinesias and off-periods, lesser years of education, and worse motor, cognitive, and mood scores. In multiple logistic and linear regression analyses, MDS-UPDRS Part III, BDI-II, gender, free access to medication, treatment with dopamine agonists alone, years of education, excessive concerns about adverse effects, and beliefs about being well-treated remained significant contributors to adherence measures. Conclusion: Educational strategies, greater involvement of PD patients in decision-making, and consideration of their beliefs and values might be of great need to improve medication adherence in this PD population.

Idioma originalInglés
Páginas (desde-hasta)1-7
Número de páginas7
PublicaciónParkinsonism and Related Disorders
EstadoPublicada - dic. 2021
Publicado de forma externa

Nota bibliográfica

Publisher Copyright:
© 2021 Elsevier Ltd


Profundice en los temas de investigación de 'Adherence to treatment in Parkinson's disease: A multicenter exploratory study with patients from six Latin American countries'. En conjunto forman una huella única.

Citar esto